PolyPid (NASDAQ:PYPD – Get Free Report) and LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, profitability, risk and earnings. Earnings and Valuation This table compares PolyPid and […]
LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) and PolyPid (NASDAQ:PYPD – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations. Valuation & Earnings This table compares LeMaitre Vascular […]
PolyPid (NASDAQ:PYPD – Get Free Report) and LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, earnings, valuation and dividends. Analyst Ratings This is a summary of recent […]
PolyPid Ltd. (NASDAQ:PYPD) Q4 2023 Earnings Call Transcript February 14, 2024 PolyPid Ltd. misses on earnings expectations. Reported EPS is $-3.97 EPS, expectations were $-2.17. PolyPid Ltd. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greeting morning and welcome to […]
More Than 100 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up; Top-line Results Expected in Second Half of 2024 New Preclinical Data Showed OncoPLEX Injected Intratumorally Reduced Tumor Volume and Improved Survival in New Animal Models Recent Successful $16 Million Financing Extends Company’s Cash Runway